These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2402792)

  • 1. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation.
    Duquesnoy RJ; White LT; Fierst JW; Vanek M; Banner BF; Iwaki Y; Starzl TE
    Transplantation; 1990 Sep; 50(3):427-37. PubMed ID: 2402792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates.
    Duquesnoy RJ; Witvliet M; Doxiadis II; de Fijter H; Claas FH
    Transpl Int; 2004 Jan; 17(1):22-30. PubMed ID: 12955350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of HLA-A,B residue mismatch acceptability for kidneys transplanted into highly sensitized patients: a report of a collaborative study conducted during the 12th International Histocompatibility Workshop.
    Duquesnoy RJ; Marrari M
    Transplantation; 1997 Jun; 63(12):1743-51. PubMed ID: 9210498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
    Barocci S; Valente U; Nocera A
    Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients.
    Lobashevsky AL; Senkbeil RW; Shoaf JL; Stephenson AK; Skelton SB; Burke RM; Deierhoi MH; Thomas JM
    Hum Immunol; 2002 May; 63(5):364-74. PubMed ID: 11975980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients.
    Duquesnoy RJ; Howe J; Takemoto S
    Transplantation; 2003 Mar; 75(6):889-97. PubMed ID: 12660520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiscreen analysis of high PRA sera for antibodies towards public and private class I antigens: implications for computer-predicted acceptable donors for kidney transplant candidates.
    Duquesnoy RJ; White LT; Iwaki Y; Vanek M
    Transplant Proc; 1991 Feb; 23(1 Pt 1):387-8. PubMed ID: 1990561
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful cadaveric renal transplantation of patients highly sensitized to HLA Class I antigens.
    Bryan CF; Shield CF; Pierce GE; Warady BA; Aeder MI; Martinez J; Luger AM; Nelson PW; Ross G; Muruve N; Mitchell SI
    Clin Transplant; 2000 Feb; 14(1):79-84. PubMed ID: 10693641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective trial of a predictive algorithm to transplant cadaver kidneys into highly sensitized patients.
    Thompson JS; Thacker L; Byrne J
    Transplantation; 2002 Apr; 73(8):1274-80. PubMed ID: 11981421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients.
    Heidt S; Haasnoot GW; van Rood JJ; Witvliet MD; Claas FHJ
    Kidney Int; 2018 Feb; 93(2):491-500. PubMed ID: 28947279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of permissible and immunogenic HLA antigens based on epitope analysis of the HLA specific antibodies produced in sensitized patients.
    Papassavas AC; Stavropoulos-Giokas C; Boletis J; Ioannou S; Iniotaki-Theodoraki A; Kostakis A
    Eur J Immunogenet; 2002 Oct; 29(5):401-7. PubMed ID: 12358849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation.
    Goodman RS; Taylor CJ; O'Rourke CM; Lynch A; Bradley JA; Key T
    Transplantation; 2006 May; 81(9):1331-6. PubMed ID: 16699463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
    Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
    Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-specific HLA class I and CREG antibodies in complement-dependent cytotoxicity-negative renal transplants.
    Kim Y; Yang CW; Moon IS; Kim M; Lim J; Park YJ; Han K; Oh EJ
    Ann Clin Lab Sci; 2010; 40(4):330-5. PubMed ID: 20947806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation.
    Lobashevsky AL; Senkbeil RW; Shoaf J; Mink C; Rowe C; Lobashevsky ES; Burke R; Hudson S; Deierhoi MH; Thomas JM
    Clin Transplant; 2000 Dec; 14(6):533-42. PubMed ID: 11127305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients.
    Rodey GE; Neylan JF; Whelchel JD; Revels KW; Bray RA
    Hum Immunol; 1994 Apr; 39(4):272-80. PubMed ID: 7520897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Calculated panel reactive antibody method for assessing the probability of kidney recipients to receive transplantation].
    Luo M; Yu L; Xiao L
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):477-81. PubMed ID: 24752091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of calculated panel reactive antibody and its potential benefits in improving the kidney allocation strategy in Taiwan.
    Shen SW; Chang CK; Gao YS; Hsu PJ; Cheng SC; Liu FY; Lo SC
    J Formos Med Assoc; 2017 Dec; 116(12):956-963. PubMed ID: 29037453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.